Endothelial cGAS–STING activation drives aortic aneurysm; blocking it helps in mice
- Single-cell data from mouse and human aneurysms placed cGAS–STING activation mainly in endothelial cells, with higher expression in ruptured than in stable human aneurysms.
- In angiotensin II–induced mouse aneurysm, the cGAS inhibitor RU.521 or the STING antagonist STING-IN-2 reduced aneurysm incidence, aortic dilation and structural damage.
- Human aneurysm tissue showed raised cGAS, STING and TBK1, and bioinformatics suggested DHFR deficiency may link DNA damage to pathway activation.
💡 Points Based on the abstract
Two different nodes, cGAS and STING, giving the same phenotype is reassuring, but both are tool compounds and angiotensin II models usually start dosing early. Translatability hinges on treating after an aneurysm is established, with rupture as the endpoint. I'd also ask whether chronic systemic STING inhibition, with its effect on interferon-based antiviral defence, is tolerable in an older vascular population.